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Background
Existing ICH-Good Clinical Practices guidelines provide
well established guidance for organizations conducting
AIDS vaccine research. However, some important proc-
esses related to conduct of clinical studies and issues spe-
cific to AIDS vaccine research are not addressed by GCP.
We developed an institutional clinical guidance docu-
ment for research partners discussing essential processes
and practices required to conduct IAVI-sponsored
research that aims to support adherence to high ethical
and quality standards. This guidance document applies to
clinical trials and observational and behavioural research
studies.
Methods
The document describes practices that have been devel-
oped and applied over the past decade of IAVI-sponsored
clinical studies. To identify key topics, we reviewed exist-
ing guidance from GCP-related documents, the UNAIDS/
WHO guidance documents ''Ethical considerations in
biomedical HIV prevention trials'' (2007) and ''Good par-
ticipatory practices for biomedical HIV prevention trials''
(2007), national regulations and guidance documents
from other research organizations. A framework and list
of key topics was circulated to collaborating investigators
and stakeholders for input.
Results
The guidance document currently addresses 17 key topics:
community engagement, informed consent and protec-
tion of human subjects, HIV VCT, risk reduction coun-
seling, male circumcision, family planning services,
sexually transmitted infections, screening and treatment,
counselling and referral for HIV-infected individuals,
referral for health services, quality assurance/quality
improvement for service delivery, laboratory manage-
ment, vaccine-induced HIV antibodies, treatment and
compensation for physical harm, post-exposure prophy-
laxis (PEP) for study staff, social impact, gender, and post-
trial access. Challenges encountered were to use language
broad enough to recommend but not require when spe-
cific procedures may conflict with local practices or
national requirements, and to determine how to effec-
tively disseminate the guidance.
Conclusion
The clinical guidance document communicates expecta-
tions for conduct of studies, including processes respon-
sive to the needs of study staff, study volunteers and
communities, to clinical research collaborators as well as
stakeholders and the larger research community.
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